FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...
Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...
Sovereign status of Native Nations necessitates nation-to-nation healthcare relationships, including treaty-informed ...
Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive ...
In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.
Cancer-related fatigue is distinct from sleep problems, even though the two symptoms often feel closely connected, according to Susanna M. Zick, professor in the Department of Fam ...
The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application from FluoGuide A/S in Copenhagen, Denmark, allowing the company to move forward in the U.S. with a ...
Stage 1 mesothelioma is localized. The cancer is confined to one side of the chest lining or one area of the abdomen and has ...
A diagnosis of Kaposi sarcoma is a significant life event, but it is a manageable condition. Because KS is so closely linked ...
Platinum-based chemotherapy produced delayed, severe GI toxicity and functional decline; clinician reassurance that symptoms ...
Amid these challenges, many young adults want to continue working or return to their jobs during treatment. Research shows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results